Skip to main content
OpenTrials
Completed

NCT Number: NCT06868368

Perceptions of Vaping Products

This clinical trial studies the effects, appeal, and abuse liability of 6-methyl nicotine (metatine) electronic cigarettes among young adults.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Abuse Tobacco Chemically-Induced Disorders Exposure Mental Disorders Substance-Related Disorders Tobacco Use Disorder

Age range

21 year–34 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

About this study

PRIMARY OBJECTIVES:

I. Assess the pharmacokinetics of metatine and nicotine electronic (e)-cigarettes.

II. Assess the abuse liability and appeal of commercial e-cigarettes containing metatine versus nicotine.

III. Determine the impact of metatine on e-cigarette puffing behavior (topography).

OUTLINE: Participants attend 3 sessions where they will be randomized to 1 of 3 types of e-cigarette. Participants will use the e-cigarette ad-libitum for 30 minutes and answer survey questions about their perceptions of the e-cigarette. Participants must also undergo 4 blood draws during the vaping session.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 21-34 years
  • Current nicotine EC user (defined as ≥ weekly use over the past 3 months)
  • Willing to provide informed consent and abstain from using any e-cigarette at least 12 hours prior to the three lab sessions
  • Read and speak English

Exclusion criteria

  • Recently coronavirus disease 2019 (COVID-19) positive (defined as a positive test in the past 30 days) or a recent COVID-19 hospitalization (defined as a hospitalization within the past 6 months)
  • Unstable or significant psychiatric conditions (past and stable conditions will be allowed)
  • History of cardiac event or distress within the past 3 months
  • Have suffered from any serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days
  • Are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test)
  • Have hemophilia or another type of bleeding disorder
  • Are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability

Treatment and study plan

Biospecimen Collection

Other

Undergo blood sample collection

Other names: Biological Sample Collection

Survey Administration

Other

Complete Surveys

Vaping Topography

Behavioral

Use e-cigarette connected to a topography device

Participant's Own Preferred E-cigarette

Other

Participant vapes their own preferred e-cigarette for 30 minutes

Nicotine E-cigarette

Other

Participant vapes a commercially available nicotine e-cigarette for 30 minutes

6-methyl-nicotine (metatine) e-cigarette

Other

Participant vapes a commercially available metatine e-cigarette for 30 minutes

Primary outcomes

  1. Pharmacokinetics of metatine and nicotine e-cigarettes

    Time frame: Pre-vaping session, Minute 5 of vaping session, Minute 15 of vaping session, Minute 30 of vaping session

    Pharmacokinetics of metatine and nicotine e-cigarettes will be examined by measuring the concentration of metatine and nicotine in blood plasma at different timepoints throughout the study vaping session.

  2. E-cigarette puffing behavior

    Time frame: Week 1, Week 2, Week 3

    E-cigarette puffing behavior will be measured with a topography device that records frequency, duration, and flow rate of e-cigarette puffs. These measures are combined to inform the overall measure of e-cigarette puffing behavior.

  3. Sensory perceptions of EC vaping experience

    Time frame: Minute 5 of vaping session, Minute 30 of vaping session

    Sensory perceptions of vaping will be measured by the Sensory E-cigarette Expectancies Scale (SEES) questionnaire. The SEES asks questions about sensory experiences associated with vaping on a scale from 0 (Never) - 4 (Almost Always).

  4. Appeal ratings

    Time frame: Minute 5 of vaping session, Minute 30 of vaping session

    Participants will rate appeal (e.g., liking, disliking) on Visual Analogue Scales (range, 0-100).

  5. Sensory ratings

    Time frame: Minute 5 of vaping session, Minute 30 of vaping session

    Participants will rate sensory attributes (e.g., harshness, coolness) on Visual Analogue Scales (range, 0-100).

  6. Relief of withdrawal symptoms

    Time frame: Pre-vaping session, Minute 5 of Vaping Session, Minute 30 of vaping session

    Nicotine withdrawal relief will be measured by the Minnesota Nicotine Withdraw Scale (MNWS). The MNWS asks users how much they are currently feeling certain nicotine withdraw symptoms on a scale of None, Slight, Moderate, Mild, or Severe.

Sponsors and collaborators

Lead sponsor

Ohio State University Comprehensive Cancer Center

Other

Registry information

Official study title

Perceptions of Vaping Products Among Young Adults

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Mar 10, 2025
Registry last updated
Dec 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.